172 related articles for article (PubMed ID: 18232729)
21. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
Ha HT; Lee JS; Urba S; Koenig RJ; Sisson J; Giordano T; Worden FP
Thyroid; 2010 Sep; 20(9):975-80. PubMed ID: 20718683
[TBL] [Abstract][Full Text] [Related]
22. [Treatment with imatinib for refractory PAH].
Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
[No Abstract] [Full Text] [Related]
23. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
24. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
26. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.
Roussidis AE; Theocharis AD; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2007; 14(7):735-43. PubMed ID: 17346159
[TBL] [Abstract][Full Text] [Related]
27. PDGF BB induces VEGF secretion in ovarian cancer.
Matei D; Kelich S; Cao L; Menning N; Emerson RE; Rao J; Jeng MH; Sledge GW
Cancer Biol Ther; 2007 Dec; 6(12):1951-9. PubMed ID: 18075302
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
[TBL] [Abstract][Full Text] [Related]
30. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy.
van Steensel L; Paridaens D; Dingjan GM; van Daele PL; van Hagen PM; Kuijpers RW; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1002-7. PubMed ID: 19797221
[TBL] [Abstract][Full Text] [Related]
31. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
Sawyers CL
J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
[No Abstract] [Full Text] [Related]
32. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
McDowell HP; Meco D; Riccardi A; Tanno B; Berardi AC; Raschellà G; Riccardi R; Dominici C
Int J Cancer; 2007 Mar; 120(5):1141-9. PubMed ID: 17131346
[TBL] [Abstract][Full Text] [Related]
34. KIT and PDGF as targets.
Verweij J
Cancer Treat Res; 2004; 120():117-27. PubMed ID: 15217221
[No Abstract] [Full Text] [Related]
35. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
36. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Kindler T; Breitenbuecher F; Marx A; Hess G; Gschaidmeier H; Gamm H; Kirkpatrick CJ; Huber C; Fischer T
Blood; 2003 Apr; 101(8):2960-2. PubMed ID: 12480706
[TBL] [Abstract][Full Text] [Related]
37. bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts.
Ohshima M; Yamaguchi Y; Kappert K; Micke P; Otsuka K
Biochem Biophys Res Commun; 2009 Apr; 381(2):165-70. PubMed ID: 19338769
[TBL] [Abstract][Full Text] [Related]
38. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
[TBL] [Abstract][Full Text] [Related]
39. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities.
Iwayama T; Olson LE
Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576
[TBL] [Abstract][Full Text] [Related]
40. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
